Focus area: Clinical trials of new agents

Once novel agents or combinations of agents are developed and tested in the laboratory, the Developmental Therapeutics Program helps translate findings into clinical practice. The Mayo Clinic Cancer Center's Phase I Clinical Trials Group consists of physicians, nurses, laboratory scientists, research assistants and statisticians who collaborate to perform early clinical testing of novel chemotherapeutic strategies developed at Mayo Clinic and elsewhere.

These clinical trials are designed to assess the safety and efficacy of new treatments. In conjunction with these clinical trials, blood samples or tumor biopsies are often examined to determine the impact of the treatment on the targeted signaling pathway.

After initial clinical trials, some treatments go on for more extensive clinical testing in phase II and phase III trials conducted in other programs within the Mayo Clinic Cancer Center, through the Mayo Clinic Phase II Consortium or through the Alliance for Clinical Trials in Oncology.

Here are specific research areas in clinical trials:

Focus area Faculty contacts
Developing kinase inhibitors for the treatment of endocrine malignancies
Hematological malignancies
  • James M. Foran, M.D.
Markers of drug response
  • Thomas J. Flotte, M.D.
Melanoma
  • Aleksandar Sekulic, M.D., Ph.D.
New therapies for chronic lymphocytic leukemia (CLL)
New therapies for the treatment of multiple myeloma
New therapies for the treatment of ovarian cancer
Phase I early trials, gastrointestinal malignancies
Phase I trial, lung cancer
Targeting the insulin-like growth factor receptor